{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-116712","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.555574+00:00","generated_at":"2026-06-08T05:06:52.189858+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"VYNE raises $88.2M, reports positive Phase 1b vitiligo data for VYN201","bullets":["$88.2M private placement closed Nov 1; cash runway extended through end of 2025.","Phase 1b: VYN201 mean F-VASI reduction 30.2% (1%) and 39.0% (2%) at 16 weeks; well-tolerated.","Phase 2b trial for VYN201 in vitiligo expected H1 2024; top-line results mid-2025.","VYN202 IND submission by year-end 2023; Phase 1a trial in Q1 2024; Phase 1b in psoriasis/RA H2 2024.","Q3 2023 GAAP net loss $6.6M, adjusted net loss $5.7M; cash runway through 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-116712","json":"https://secwatch.observer/filing/0001104659-23-116712.json","markdown":"https://secwatch.observer/filing/0001104659-23-116712.md","text":"https://secwatch.observer/filing/0001104659-23-116712.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000110465923116712/0001104659-23-116712-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000110465923116712/tm2330394d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:06:52.189858+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0e46ad67fcc777798f44461ed3a6044d3c8cec15","claim":"VYNE Therapeutics Inc. reported financial results for the three and nine months ended September 30, 2023.","evidence_excerpt":"On November 13, 2023, VYNE Therapeutics Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465923116712/0001104659-23-116712-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and nine months ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}